Children's Oncology Group's 2013 blueprint for research: Rare tumors |
| |
| Authors: | Carlos Rodriguez‐Galindo MD Mark Krailo PhD Lindsay Frazier MD Murali Chintagumpala MD James Amatruda MD Howard Katzenstein MD Marcio Malogolowkin MD Logan Spector PhD Farzana Pashankar MD Rebecka Meyers MD Gail Tomlinson MD PhD |
| |
| Affiliation: | 1. Dana‐Farber/Children's Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts;2. Department of Statistics, Children's Oncology Group, University of Southern California, Arcadia, California;3. Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas;4. University of Texas Southwestern Medical Center, Dallas, Texas;5. Children's Healthcare of Atlanta, Atlanta, Georgia;6. Midwest Children's Cancer Center, University of Wisconsin, Milwaukee, Wisconsin;7. University of Minnesota Medical Center, Minneapolis, Mississippi;8. Yale University, New Haven, Connecticut;9. Primary Children's Medical Center, Salt Lake City, Utah;10. University of Texas Health Science Center, San Antonio, Texas |
| |
| Abstract: | In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5‐year survival ranging from <20% for children with advanced carcinomas to >95% for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence‐based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers. Pediatr Blood Cancer 2013; 60: 1016–1021. © 2012 Wiley Periodicals, Inc. |
| |
| Keywords: | germ cell tumors hepatoblastoma rare cancers retinoblastoma |
|
|
